VIP benefits, on this page, means the effects of vasoactive intestinal peptide, a 28-amino-acid neuropeptide used as a nasal spray in mold illness (CIRS) protocols and, as aviptadil, in clinical trials. It does not cover VIP memberships, tickets or loyalty perks. Below, each claimed benefit is graded by how it was tested, followed by what six Reddit users said. For the overview of the molecule, see our VIP peptide guide.
Key Takeaways
- The best-tested benefit is physiological: inhaled or injected VIP relaxes blood vessels and airways, and in two small human studies it lowered inflammatory signals or pulmonary pressure briefly.
- The two largest randomized trials, of intravenous aviptadil in COVID-19 respiratory failure, found no survival benefit when pooled (odds ratio 1.01).
- The CIRS nasal spray case rests on one open-label study of 20 patients with no placebo group.
- Only 6 usable first-hand Reddit accounts exist in the data I reviewed, and 5 of them describe feeling worse or over-sensitive early on.
- VIP is not FDA-approved for any use. It is sold as a research chemical or compounded to prescription.
Which VIP this page covers
Search results for "VIP benefits" are dominated by insurance programs, streaming shows and event packages, so a clarification helps. Vasoactive intestinal peptide was first isolated from gut tissue, but it is made in the brain, lungs and immune cells too. It binds three receptors (VPAC1, VPAC2 and PAC1) and raises cyclic AMP inside cells, which relaxes smooth muscle and shifts how immune cells behave.
Two names matter. "VIP" is the natural peptide. "Aviptadil" is the synthetic version used in hospital trials. Most of the human data below uses aviptadil, given intravenously or inhaled, not a nasal spray. That gap matters for every claim that follows.
Three practical points frame the rest. First, VIP is broken down in blood within minutes, which is why trials infuse it continuously or inhale it and why nasal spray protocols dose several times a day. Second, whether a nasal spray delivers meaningful VIP to the brain has not been measured in humans, a point our CIRS nasal spray article covers in detail. Third, regulators treat it as unapproved: on the FDA's 503A list, updated May 14, 2026, vasoactive intestinal peptide sits in Category 1, "under evaluation", which lets licensed pharmacies compound it for now. That is an interim status, not an approval.
VIP benefits by evidence tier
Ordering the evidence from strongest to weakest makes the picture clearer than any list of benefits.
Human randomized trials. These exist for aviptadil, not for nasal VIP. A 196-patient placebo-controlled trial of 3 days of intravenous aviptadil in COVID-19 respiratory failure missed its primary endpoint (alive and free of respiratory failure at day 60, odds ratio 1.6, 95% CI 0.86 to 3.11), although it reported a two-fold odds of survival at 60 days (OR 2.0, 95% CI 1.1 to 3.9) and a drop in interleukin 6 (PMID 36044317). The larger TESICO trial then enrolled 461 patients in the aviptadil comparison and found an odds ratio of 1.11 (95% CI 0.80 to 1.55) for a better outcome category at day 90, with death by day 90 in 38% on aviptadil and 36% on placebo (PMID 37348524). A 2025 meta-analysis of the two randomized trials put the survival odds ratio at 1.01 (95% CI 0.72 to 1.42), "no significant benefit" in its own words (PMID 41368449).
Small human studies. An 80-patient randomized trial of inhaled aviptadil in hospitalized COVID-19 reported discharge at 7.8 days versus 10 days on placebo (p = 0.049) and deaths of 5.1% versus 12.2%, a difference the trial was too small to test (PMID 39870064). Earlier, eight patients with primary pulmonary hypertension showed lower pulmonary artery pressure on VIP (PMID 12727925), and 20 patients inhaling a single 100 microgram dose saw a "small and temporary" vasodilation that the authors called modest and short-lived (PMID 18978135). In 20 sarcoidosis patients, 4 weeks of nebulized VIP reduced TNF-alpha production by lung cells and increased regulatory T cells, in an open study with no control group (PMID 20442436).
Animal and cell work. Reviews describe exogenous VIP producing therapeutic effects in animal models of autoimmune and inflammatory disease through VPAC1 and VPAC2 receptors (PMID 31861827). That is the source of most claims about gut, joint and brain inflammation. It is hypothesis-generating, not proof in people.
Anecdote. Covered below.
The figure puts each claim on its tier.
VIP benefits by evidence tier
| What was studied | How far it goes | |
|---|---|---|
| Human RCT | IV aviptadil in COVID-19 respiratory failure (196 and 461 patients), plus an inhaled trial in 80 | No survival benefit in the larger trials; one small inhaled trial shortened hospital stay |
| Small human | Inhaled VIP in pulmonary hypertension (8 and 20 patients) and sarcoidosis (20 patients, open label) | Short-lived vasodilation, lower TNF-alpha, more regulatory T cells; no lasting clinical outcome |
| Other product | Aviptadil plus phentolamine injected into the penis for erectile dysfunction (308 men, retrospective) | 59% found it effective; a different drug, dose and route from any nasal spray |
| Open label | VIP nasal spray in CIRS (20 patients, no placebo, by the protocol's author) | Large reported gains, uncontrolled, not independently replicated |
| Animal and cell | Cytokine suppression, regulatory T cells, models of autoimmune and inflammatory disease | Not shown in people at nasal-spray doses |
| Anecdote | 6 first-hand Reddit accounts, almost all from CIRS patients | Mostly early side effects; a few reported later improvement |
The one licensed VIP product is not a spray
One VIP-derived product has real regulatory standing, and it has nothing to do with sprays. Aviptadil combined with phentolamine, injected into the penis, is a licensed erectile dysfunction treatment in the UK, where Scottish and Welsh health bodies limit it to men who failed oral drugs, based on NHS formulary documents. A 2025 retrospective of 308 men who had failed or could not tolerate alprostadil injections found 59% called it effective, with facial flushing the most common adverse event at 22.5% (PMID 40192471). That tells you VIP's vasodilation is genuine and clinically usable. It does not tell you anything about a nasal spray for fatigue, brain fog or mold illness.
VIP benefits in CIRS: the protocol claim
The biggest consumer interest in VIP benefits comes from chronic inflammatory response syndrome, the diagnosis many mold-illness patients use. In the Shoemaker protocol, VIP is the last step, after exposure removal, binders and several other corrections. Support for it comes from a 2013 open-label study of 20 patients treated by the protocol's author, with no placebo and comparison to historical controls; our CIRS article goes through its numbers and flaws.
Newer papers are thin. A 2024 literature review concluded that the Shoemaker protocol was the only CIRS treatment with documented clinical efficacy, but it judged the whole sequence, not VIP alone (PMID 39649915). A 2026 retrospective of 188 patients from one clinic found blood VIP rose by about 20 pg/mL between visits, and tied alpha-MSH changes to clearing a nasal bacterial colonization, which is an association in a single site's records, not a test of the spray (PMID 42077435). A rising blood level is also not the same as feeling better.
CIRS itself remains contested among mainstream bodies. A benefit that can only be measured inside a framework others dispute is a weaker benefit than the same size of effect in a conventional trial.
Claims with no human support
Several benefits circulate that I could not support from the sources I checked. A Reddit user asked about VIP for alopecia areata; the thread had no replies in the data, and I found no controlled human data for it. Claims for improved cognition, memory, PTSD, circadian stability, gut healing and cerebral blood flow rest on animal findings and mechanism. They are plausible, and they are also the claims most often repeated by sellers. A Peptidesource poster in September 2026 noted that practical information on using VIP is very limited, which matches what the literature shows.
What Reddit users report
I reviewed 507 scraped items. 480 were unrelated: VIP as a ticket tier, game currency or fan-club perk in r/Marathon, r/Maplestory, r/gachagaming, r/bangtan and r/Keep_Track, plus a 2021 stock-promotion thread about aviptadil in r/SPACs, a card-game post and a K-pop post. Nine more were a vendor announcement about other peptides in r/Cymnootropics. Of the remainder, 6 were first-hand accounts of using VIP: one original post and five comments, all in a single r/CIRS thread from June 2026, cross-posted to r/ToxicMoldExposure and r/Lyme without replies. Three more comments were advice or hearsay from people not using it. Because this is far fewer than 15 usable reports, treat everything here as illustration only.
The pattern was consistent but tiny. Five of the six described feeling worse, over-sensitive or anxious early, and four had lowered or slowed their dose in response. Three reported improvement later. One original poster, one week into 4 sprays a day, described anxiety, bloating and feeling "off" and asked for people who felt worse before better. The replies were mostly about going slower, including one person on 3 sprays a week and another who dropped to a single spray in alternating nostrils.
What 6 Reddit users said about VIP
One commenter wrote: "Even on this small dose I felt worse than I did before I started. I am starting to feel better now." (a r/CIRS commenter, Jun 2026) Another wrote: "Slowly but surely my brain started to come back online. My concentration and comprehension improved..." (a r/CIRS commenter, Jun 2026) That user said they had to start with a very low dose and increase slowly.
The cautionary account: "I started on the full dose in error (did not taper up) and after 10 days I became very unwell." (a r/CIRS commenter, Jun 2026) A different commenter said one spray of a 1% dilution affected them strongly. Those reports are consistent with VIP being a vasodilator and nervous-system signal, but they are unverified and cannot prove cause.
Outliers. One commenter said they inject 100 mcg a day and feel good, with no detail on source, duration or monitoring. A clinician posting in r/ToxicMoldExposure in February 2026 described VIP as under-used and recommended homeopathic alternatives, which is a professional's opinion with no data and not a user report. Neither is evidence of safety or benefit. Note also that everyone in this sample is already unwell, chose to post, and may be taking many other treatments.
How long users say it takes
Few commenters gave a timeframe, and the ones who did describe a rough start rather than a fast win. Anecdotes ranged from worsening in the first week or two to starting to feel better after about a month on a low dose.
When Reddit users said things changed
- 1 week
The original poster, on 4 sprays a day, felt anxious, bloated and 'off' - 10 days
One user who started a full dose without tapering became very unwell - 2 weeks
One user at 2 sprays a day held there before stepping up to 3 - About 1 month
One user on 3 sprays a week said they were starting to feel better
Nothing here supports expecting an effect from a single dose. Reported improvement, where any, arrived after slow titration, and it is impossible to separate from the other steps CIRS patients take in the same months.
Honest limits
Four problems recur. The human trials used aviptadil in critically ill or hospitalized patients, not a spray in outpatients. The outpatient evidence is uncontrolled. VIP's short half-life makes lasting benefit from intermittent nasal doses a question nobody has measured. And Reddit reports from the same thread share a single context, so they are not six independent confirmations.
Who should be cautious
Because VIP lowers blood pressure and can cause flushing, headache and loose stools, people on blood pressure medication, those with low blood pressure, and anyone pregnant or with pancreatic problems should speak with a prescriber before using it. The CIRS protocol checks lipase before starting. Our side effects and monitoring section and overview cover documented adverse effects.
Price and sourcing of research-grade VIP
On 2026-10-11, Ascension Peptides lists VIP 10 mg at $58.00 (list price $149.99), about $5.80 per mg. Ascension says Kovera Labs tests every batch for HPLC purity, LC-MS identity, net content, endotoxin, sterility and heavy metals, with over 98% of batches passing and public batch COAs. Prices are in USD, shipping is US only, and all sales are final. New customers can use code PEPTIDEDECK for 50% off. Prices move, so check the product page. Our where to buy VIP guide explains what to check on any certificate.
A purchase does not change the evidence above. Research-grade VIP is not a medicine and has no dosing instructions.
Frequently Asked Questions
What are the benefits of VIP?
VIP relaxes blood vessels and airways and modulates immune signals. In small human studies it lowered pulmonary pressure or TNF-alpha briefly. Large COVID-19 trials of intravenous aviptadil found no survival benefit, and most other claimed benefits rest on animal data or uncontrolled reports.
What are the benefits of VIP nasal spray?
Claimed benefits center on CIRS, but the evidence is one open-label study of 20 patients with no placebo. Reddit reports in this review were mixed, with early worsening common and later improvement in some.
Does VIP peptide work for mold illness?
It is the last step of a contested protocol. No placebo-controlled trial of VIP for CIRS has been published that I could find, so the answer is unproven.
Is VIP peptide safe?
Short human studies reported flushing, low blood pressure, headache and loose stools. Long-term safety in healthy people is not documented. Our overview lists monitoring points.
Is VIP peptide FDA approved?
No. VIP is on the FDA's 503A Category 1 "under evaluation" list as of May 14, 2026, which is not approval. Aviptadil is not approved in the US.
Where to buy research-grade VIP
If you decide to buy research material despite the thin evidence, Ascension Peptides lists VIP 10 mg at $58.00 as of 2026-10-11, with Kovera Labs batch testing and public COAs. Weigh the evidence first, and speak with a clinician if you have a condition or take medication.
Medical Disclaimer: VIP sold as a research product is not approved by the FDA for any condition and is not intended for human consumption. This article is educational, summarizes published studies and anonymous online reports, and is not medical advice or a recommendation to use any product. Consult a qualified healthcare professional about any health concern.
